April 14, 2021
Business News

MPM Capital Strengthens Team with the Addition of Neuroscience R&D Leader David S. Bredt, MD, PhD as Executive Partner

CAMBRIDGE, Mass.–()–MPM Capital (MPM), a leading biotechnology investment firm investing in early-stage therapeutics companies, today announced that David S. Bredt, MD, PhD, has joined its team of Executive Partners.

“We’re delighted to have David join MPM. His drug discovery expertise will be broadly applied to the MPM portfolio with a particular emphasis on building new companies addressing disorders of the central nervous system,” said Ed Hurwitz, managing director at MPM Capital. “We see tremendous advances in the understanding of neurological dysfunction particularly in the areas of protein trafficking, neuroinflammation, neuroregeneration and ion-channel modulation. We fully expect David’s…

Click here to view the original article.

Related Posts

You might also like ...

Bundesgerichtshof entscheidet zu Gunsten von Solvay im Patentstreit mit Neo
Fraunhofer and Sinclair to Collaborate Towards Integrating Digital Radio Mondiale Framework into the ATSC 3.0 Digital TV Platform
Sopheon Bridges Gaps Between Digital and Physical Product Development with Launch of Accolade for Smart Products